<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111424412</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111424412</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Anti–Tumor Necrosis Factor–α Monoclonal Antibody Alleviates Parenteral Nutrition–Associated Liver Disease in Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Jing</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111424412">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gong</surname><given-names>Yi-ming</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0148607111424412">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Jiang</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111424412">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Wen-jie</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0148607111424412">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Cai</surname><given-names>Wei</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111424412">1</xref>
<xref ref-type="aff" rid="aff2-0148607111424412">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607111424412"><label>1</label>Clinical Nutrition Center</aff>
<aff id="aff2-0148607111424412"><label>2</label>Department of Pediatric Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China</aff>
<author-notes>
<corresp id="corresp1-0148607111424412">Wei Cai, MD, PhD, Clinical Nutrition Center and Department of Pediatric Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai 200092, China; e-mail: <email>zzhlq3@gmail.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>2</issue>
<fpage>219</fpage>
<lpage>225</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>7</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>8</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: The authors aimed to investigate the role of anti–tumor necrosis factor (TNF)–α monoclonal antibody treatment in a mouse model of parenteral nutrition–associated liver disease (PNALD). <italic>Methods</italic>: C57BL/6J male mice (aged 6–8 weeks) were randomly assigned to 3 groups: parenteral nutrition (PN), PN with anti–TNF-α monoclonal antibody treatment (PN + mAb), and controls. A central venous catheter was inserted for intravenous infusion of a PN solution (PN and PN + mAb groups) or saline (controls) for 7 days. Liver pathology, hepatic biochemical indicators, and serum TNF-α concentrations were analyzed. Levels of hepatic <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> mRNA were also evaluated in each group. <italic>Results</italic>: The PN group showed significant increases in serum transaminase, direct bilirubin, and bile acids relative to the control group (<italic>P</italic> &lt; .05). Histopathological changes in this group were consistent with early stage cholestasis. The pathological score and serum alanine aminotransferase, total bilirubin, and direct bilirubin levels were improved in the PN + mAb group relative to the PN group (<italic>P</italic> &lt; .05). The PN group showed significantly lower hepatic <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> mRNA expression than the controls (<italic>P</italic> &lt; .05), but these were significantly increased compared to the PN group (<italic>P</italic> &lt; .05). <italic>Conclusions</italic>: Infliximab administered at a single dose of 5 mg/kg body weight ameliorated the progression of PNALD and improved the expression of hepatic ABC transporter genes. Therefore, anti–TNF-α monoclonal antibody may be a beneficial therapy for patients with PNALD.</p>
</abstract>
<kwd-group>
<kwd>tumor necrosis factor–α</kwd>
<kwd>parenteral nutrition</kwd>
<kwd>liver disease</kwd>
<kwd>adenosine triphosphate binding cassette transporters</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The advent of parenteral nutrition (PN) has led to significant improvements in the nutrition status and prognosis of patients with intestinal failure. The PN formula, which consists of lipids, amino acids, carbohydrates, electrolytes, vitamins, and trace elements, promotes a multiorgan adaptation response. The liver plays a crucial role in the metabolism of endobiotics and xenobiotics, and the first case of PN-associated liver disease (PNALD) was reported in 1971. The hepatic detoxification mechanisms of many compounds and metabolites, including metabolic conversion and elimination, mainly depend on the hepatobiliary transport process mediated by the hepatocyte apical adenosine triphosphate (ATP)–binding cassette (ABC) transporter superfamily.<sup><xref ref-type="bibr" rid="bibr1-0148607111424412">1</xref>,<xref ref-type="bibr" rid="bibr2-0148607111424412">2</xref></sup> The ABC transporters are a family of proteins, including the bile salt export pump (<italic>bsep</italic>), multidrug resistance 1 protein (<italic>mdr1a</italic>/<italic>mdr1b</italic>: transports chemotherapy drugs into bile), multidrug resistance protein P-glycoprotein (<italic>mdr2</italic>: transports phosphatidylcholine), and multidrug resistance–associated protein (<italic>mrp2</italic>: transports bile acids and potential toxins into the bile canaliculi).<sup><xref ref-type="bibr" rid="bibr1-0148607111424412">1</xref>,<xref ref-type="bibr" rid="bibr3-0148607111424412">3</xref>-<xref ref-type="bibr" rid="bibr5-0148607111424412">5</xref></sup> Moreover, a series of studies have suggested that the pathogenesis of some forms of cholestasis could be attributed to mutations in the ABC transporter gene.<sup><xref ref-type="bibr" rid="bibr3-0148607111424412">3</xref>,<xref ref-type="bibr" rid="bibr6-0148607111424412">6</xref>,<xref ref-type="bibr" rid="bibr7-0148607111424412">7</xref></sup> PNALD manifests most commonly with steatosis in adults and with cholestasis in infants. Severe cases of PNALD may lead to end-stage liver disease, including biliary cirrhosis, hepatic fibrosis, and hepatic failure. Clinical data have shown that PNALD is associated with prolonged PN, liver immaturity, frequent episodes of sepsis, essential nutrient deficiency, and contamination of the PN solution.<sup><xref ref-type="bibr" rid="bibr8-0148607111424412">8</xref>,<xref ref-type="bibr" rid="bibr9-0148607111424412">9</xref></sup> However, the molecular mechanisms underlying PNALD remain unclear.</p>
<p>Tumor necrosis factor–α (TNF-α), a cytokine with diverse biological functions related to cytotoxicity, inflammation, growth stimulation, and immune modulation, has previously been shown to be elevated in PN rats.<sup><xref ref-type="bibr" rid="bibr10-0148607111424412">10</xref></sup> TNF-α –/– mice with experimental cholestasis exhibited significantly higher survival rates than wild-type mice with experimental cholestasis, which suggests that TNF-α may play an important role in the development of cholestasis-induced end-stage liver disease.<sup><xref ref-type="bibr" rid="bibr11-0148607111424412">11</xref></sup> Forrest et al<sup><xref ref-type="bibr" rid="bibr12-0148607111424412">12</xref></sup> reported TNF-α antibody treatment of a patient with Crohn disease who developed PN-associated cholestasis (PNAC) with complications, including multiple fistulae and short bowel syndrome. In this case, TNF-α antibody treatment led to a decrease in biochemical and histological markers of PNAC, suggesting that TNF-α may act as a proinflammatory cytokine with a critical role in the development of PNALD. The monoclonal TNF-α antibody (infliximab) used in this study neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α and inhibiting TNF-α binding to its receptors.<sup><xref ref-type="bibr" rid="bibr13-0148607111424412">13</xref>,<xref ref-type="bibr" rid="bibr14-0148607111424412">14</xref></sup> It is used to treat Crohn disease, rheumatoid arthritis, and other autoimmune diseases with its immunosuppressive effect. The current study aimed to determine the effect of TNF-α antibody (infliximab) with PN in a mouse model of PNALD.</p>
<sec id="section1-0148607111424412" sec-type="methods">
<title>Methods</title>
<sec id="section2-0148607111424412">
<title>PNALD Mouse Model</title>
<p>C57BL/6J male, specific pathogen-free mice (aged 6–8 weeks), weighing between 20 and 25 g, were obtained from the SLAC Laboratory Animal facility (Shanghai, China) and maintained in a 12:12-hour day-night cycle at a constant temperature of 23°C and a relative humidity between 40% and 60%. Mice were initially fed ad libitum with standard mouse chow and water and allowed to acclimatize for 7–10 days.<sup><xref ref-type="bibr" rid="bibr15-0148607111424412">15</xref></sup> After the mice were disinfected and anesthetized with 350 mg/kg intraperitoneal chloral hydrate, a 1.2-mm external diameter heparin-flushed peripherally inserted central catheter (PICC) was inserted through the isolated right jugular vein into the superior vena cava. The PICC jacket tube was fixed by suture to the dorsal skin of the mice. At 24 hours postsurgery, the surviving mice were allocated randomly to 3 groups: PN, PN with monoclonal TNF-α antibody treatment (PN + mAb), and a saline control group (control). Mice in the PN and PN + mAb groups were deprived of food and fed only by intravenous infusion with a PN solution. The control group received normal saline 0.9% (NS) by intravenous infusion and was permitted free access to food. Mice were housed individually, and the PN solution was delivered through a micro-pump (IVAC ALARIS P3000 Syringe Pump; Alaris Medical Systems, Basingstoke, UK) by continuous intravenous infusion at a rate of 7.2 mL/24 h. The PN solution was prepared under sterile conditions as an all-in-one balanced mix (Table l) of amino acids, lipids, and dextrose in addition to electrolytes, trace elements, and vitamins (thermal nitrogen ratio: 285:71). After 7 days of PN or NS infusion, followed by 2 hours of NS infusion, mice were weighed and sacrificed using CO<sub>2</sub>. All liver tissues were harvested from each mouse, and blood samples were collected and stored at −20°C for serum biochemical tests and TNF-α concentration. A portion of each liver sample was fixed in 10% formalin, dehydrated by treatment with a graded series of ethanol, and embedded in paraffin. The tissue was sectioned (4 µm thick), stained with hematoxylin and eosin (H&amp;E), and examined by light microscopy (LM). The remaining portions of each liver sample were sliced into approximately equal quantities and frozen at −70°C for messenger RNA (mRNA) expression analysis.</p>
<p>The Shanghai Jiao Tong University School of Medicine Animal Ethics Committee approved this entire protocol.</p>
</sec>
<sec id="section3-0148607111424412">
<title>Anti–TNF-α Monoclonal Antibody</title>
<p>Infliximab was purchased from Cilag AG (Schaffhausen, Switzerland). Administration of infliximab was carried out according to in vivo pharmacokinetic and pharmacodynamic data in the drug manual,<sup><xref ref-type="bibr" rid="bibr16-0148607111424412">16</xref></sup> as well as efficacy data in the rodent’s model of liver injury.<sup><xref ref-type="bibr" rid="bibr17-0148607111424412">17</xref>-<xref ref-type="bibr" rid="bibr19-0148607111424412">19</xref></sup> The antibody dose via intravenous (IV) infusion was converted from a dose used in rats to a dose based on surface area for mice by multiplying 10 mg/kg<sup><xref ref-type="bibr" rid="bibr20-0148607111424412">20</xref></sup> (Pappo’s rat dose) by the K<sub>m</sub> factor<sup><xref ref-type="bibr" rid="bibr6-0148607111424412">6</xref></sup> for rats and then dividing by the K<sub>m</sub> factor<sup><xref ref-type="bibr" rid="bibr3-0148607111424412">3</xref></sup> for mice. The PN + mAb group was dosed on the third day of PN infusions with 5 mg/kg antibody via a single IV infusion of 400 µg/mL solution infused over a period of no less than 2 hours.</p>
</sec>
<sec id="section4-0148607111424412">
<title>Pathological Manifestation</title>
<p>The same pathologist, who was blinded to the group assignment, evaluated each liver sample. The pathological scoring system used has been described previously: 0 = normal modality without degeneration; 1 = mild hydropic or fatty degeneration, with mild to moderate inflammatory cell infiltration; 2 = moderate degenerative changes; and 3 = hepatonecrosis, bile pigmentation, or mild fibrosis.<sup><xref ref-type="bibr" rid="bibr21-0148607111424412">21</xref>,<xref ref-type="bibr" rid="bibr22-0148607111424412">22</xref></sup></p>
</sec>
<sec id="section5-0148607111424412">
<title>Biochemical Indicators</title>
<p>Analysis of hepatic biochemical indicators, including the levels and/or activity of serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), total bilirubin (Tbil), direct bilirubin (Dbil), and bile acid (BA), was performed using an automatic biochemical analyzer (7150 system, Hitachi, Tokyo, Japan). Hemolytic serum specimens were excluded, and the performance of serological indexes depended on the amount of serum samples.</p>
</sec>
<sec id="section6-0148607111424412">
<title>Enzyme-Linked Immunosorbent Assay</title>
<p>After the biochemical analysis, TNF-α concentration was determined in the remaining serum samples by enzyme-linked immunosorbent assay (ELISA) using commercially available kits (R&amp;D Systems, Minneapolis, MN) according to the instructions supplied by the manufacturer.</p>
</sec>
<sec id="section7-0148607111424412">
<title>mRNA Expression</title>
<p>The mRNA expression levels of hepatic <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> were measured using reverse-transcriptase polymerase chain reaction (RT-PCR) techniques and a standard curve-based method for relative quantification in real-time PCR data processing.<sup><xref ref-type="bibr" rid="bibr23-0148607111424412">23</xref></sup> Total cellular RNA was obtained from liver using TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA), according to the instructions of the manufacturer. Purified RNA samples were frozen at −70°C prior to cDNA synthesis. Then, 2 µg of RNA was combined with 1 µL of 0.5 µg/µL Oligo(dT)<sub>18</sub> (Sangon, Shanghai, China) and 3.2 µL of 2.5 mM dNTP mix (HyTest Ltd, Turku, Finland). RNase-free H<sub>2</sub>O was added to give a total reaction volume of 13 µL. This mixture was incubated at 65°C for 5 minutes and then incubated on ice for 2 minutes. The RT reaction mixture was transferred to a microcentrifuge tube containing 4 µL of 5× First-Strand Buffer (Invitrogen Life Technologies), 1 µL of 0.1 M dithiothreitol (DTT), 1 µL of RNase Inhibitor (Epicentre, Madison, WI), and 1 µL of SuperScript III Reverse Transcriptase (Invitrogen Life Technologies). The sample mixture was incubated at 50°C for 60 minutes and 70°C for 15 minutes and stored at −20°C until the PCR was performed. The PCR mixture contained 0.4 µL of each 10-µM primer pair, 1 µL of 2.5 mM dNTPs (HyTest Ltd), 1 µL of 10× PCR buffer (Promega, Madison, WI), 0.6 µL of 25 mM MgCl<sub>2</sub> (Promega, Madison, WI), 0.5 units of <italic>Taq</italic> polymerase (Promega), a final concentration of 0.25 × SYBR green dye (Invitrogen Life Technologies), and 0.2 µL 2× ROX reference dye (Invitrogen Life Technologies). Water was added to give a total reaction volume of 8 µL. Primer pairs were designed using the Primer 3 PCR primer design tool (Geeknet, Inc, Mountain View, CA) and were based on the GeneBank accession number for the corresponding mouse mRNA. The DNA sequences of the primers and hybridization probes are provided in <xref ref-type="table" rid="table2-0148607111424412">Table 2</xref>. PCR reactions for each mRNA and primer pair were carried out using the following thermocycler settings: 40 cycles of 95°C for 15 seconds, 59°C for 20 seconds, and 72°C for 5 minutes. Results were examined at the exponential phase of the PCR curve and expressed relative to β-actin expression levels, which were determined for each sample and served as a control.</p>
<table-wrap id="table1-0148607111424412" position="float">
<label>Table 1.</label>
<caption>
<p>Formulation of Nutrient Solution</p>
</caption>
<graphic alternate-form-of="table1-0148607111424412" xlink:href="10.1177_0148607111424412-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Components</th>
<th align="center">Volume, mL</th>
<th align="center">Kcal</th>
<th align="center">% of Calories</th>
</tr>
</thead>
<tbody>
<tr>
<td>50% glucose</td>
<td>40</td>
<td>80.0</td>
<td>61.44</td>
</tr>
<tr>
<td>8.5% amino acids</td>
<td>30</td>
<td>10.20</td>
<td>7.83</td>
</tr>
<tr>
<td>20% MCT/LCT</td>
<td>20</td>
<td>40.0</td>
<td>30.72</td>
</tr>
<tr>
<td>10% sodium chloride</td>
<td>3</td>
<td/>
<td/>
</tr>
<tr>
<td>10% potassium chloride</td>
<td>0.3</td>
<td/>
<td/>
</tr>
<tr>
<td>10% calcium gluconate</td>
<td>0.3</td>
<td/>
<td/>
</tr>
<tr>
<td>Water-soluble vitamins</td>
<td>0.2</td>
<td/>
<td/>
</tr>
<tr>
<td>Fat-soluble vitamins</td>
<td>0.2</td>
<td/>
<td/>
</tr>
<tr>
<td>Total</td>
<td>94.0</td>
<td>130.20</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111424412">
<p>LCT, long-chain triglyceride; MCT, medium-chain triglyceride.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0148607111424412" position="float">
<label>Table 2.</label>
<caption>
<p>Primer Information</p>
</caption>
<graphic alternate-form-of="table2-0148607111424412" xlink:href="10.1177_0148607111424412-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Gene</th>
<th align="center">Primer Sequence (5′-3′)</th>
<th align="center">Product Length, bp</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>Forward: 5′-CCTCTATGCCAACACAGTGC-3′Reverse: 5′-GTACTCCTGCTTGCTGATCC-3′</td>
<td>211</td>
</tr>
<tr>
<td>bsep</td>
<td>Forward: 5′-GCTGCCAAGGATGCTAATGC-3′Reverse: 5′-TTTGCTTCTGCCCACCACTC-3′</td>
<td>106</td>
</tr>
<tr>
<td>mdr1</td>
<td>Forward: 5′-TTCTTTCAGGGCTTCACATTTG-3′Reverse: 5’-TCCCGAGGTTTGCTACATTCT-3′</td>
<td>223</td>
</tr>
<tr>
<td>mdr2</td>
<td>Forward: 5′-CACTTCTGCTGTTATCGGTTGTT-3′Reverse: 5′-ATGAATGCTTGGGAGATGCTA-3′</td>
<td>274</td>
</tr>
<tr>
<td>mrp2</td>
<td>Forward: 5′-TGTAACATCAAGAGCACCGAGA-3′Reverse: 5′-GCAGTCCAATGGAGGCAATA-3′</td>
<td>148</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section8-0148607111424412">
<title>Statistical Analyses</title>
<p>We used the Statistical Package for the Social Sciences (SPSS) for Windows 11.5 statistical software for statistics (SPSS, Inc, an IBM Company, Chicago, IL). Data were expressed as mean ± standard deviation (range). Data analysis was performed using 1-way analysis of variance (ANOVA) or the rank-sum test and bivariate correlations analysis, and <italic>P</italic> &lt; .05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section9-0148607111424412" sec-type="results">
<title>Results</title>
<sec id="section10-0148607111424412">
<title>Examination of Liver Pathology</title>
<sec id="section11-0148607111424412">
<title>PN + mAb Group (n = 10)</title>
<p>Inflammatory infiltration in portal areas and some hepatocellular hydropic or fatty degeneration, without cholestasis or diffuse necrosis, was observed in 9 of 10 mice in this group (<xref ref-type="fig" rid="fig1-0148607111424412">Figure 1A</xref>).</p>
<fig id="fig1-0148607111424412" position="float">
<label>Figure 1.</label>
<caption>
<p>Pathological examination by light microscopy of the 3 groups (hematoxylin and eosin staining, 40×). (A) Parenteral nutrition + monoclonal antibody treatment (PN + mAb) group = mild inflammatory infiltration and hydropic degeneration, no diffuse necrosis or cholestasis. (B) PN group = hepatic intracellular cholestasis (arrows). (C) Control group = normal morphology. (D) The case number of pathological scores in 3 groups. The differences among the groups were significant, <italic>P</italic> = .000 &lt; .05 (χ<sup>2</sup> = 18.286) by the Kruskal-Wallis <italic>H</italic> test.</p>
</caption>
<graphic xlink:href="10.1177_0148607111424412-fig1.tif"/>
</fig>
</sec>
<sec id="section12-0148607111424412">
<title>PN Group (n = 13)</title>
<p>LM showed the moderate to severe hydropic degeneration in 12 of 13 mice in this group, and bile pigments were found in 3 samples (<xref ref-type="fig" rid="fig1-0148607111424412">Figure 1B</xref>).</p>
</sec>
<sec id="section13-0148607111424412">
<title>Control Group (n = 10)</title>
<p>Examination of the control group by LM showed some inflammatory infiltration without degeneration or cholestasis in 2 of 10 mice (<xref ref-type="fig" rid="fig1-0148607111424412">Figure 1C</xref>).</p>
</sec>
</sec>
<sec id="section14-0148607111424412">
<title>Histological Scoring of Liver Samples</title>
<p>The mean ± SD pathological scores for the PN group (2.20 ± 0.99) were significantly higher than both the control group (0.20 ± 0.42) and the PN + mAb group (1.20 ± 0.63) (Z = −3.698 and −2.434, respectively; <italic>P</italic> &lt; .05; <xref ref-type="fig" rid="fig1-0148607111424412">Figure 1D</xref>).</p>
</sec>
<sec id="section15-0148607111424412">
<title>Biochemical Indicators</title>
<p>Serum biochemical indicators for the PN group (n = 8 or 9), including ALT, AST, Dbil, and BA, were significantly higher than those of the control group (n = 8) (<italic>P</italic> &lt; .05; <xref ref-type="table" rid="table3-0148607111424412">Table 3</xref>). The mean ALT, Tbil, and Dbil levels of the PN + mAb group (n = 8) were significantly lower than that of the PN group (<italic>P</italic> &lt; .05). The serum levels of AST and BA were lower than the levels present in the PN group, although none of the differences were statistically significant.</p>
<table-wrap id="table3-0148607111424412" position="float">
<label>Table 3.</label>
<caption>
<p>Comparison of Biochemical Indicators Detected in the 3 Treatment Groups</p>
</caption>
<graphic alternate-form-of="table3-0148607111424412" xlink:href="10.1177_0148607111424412-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">Group (n), Mean ± SD (Range)</th>
<th/>
<th/>
</tr>
<tr>
<th/>
<th align="center">PN + mAb (8)</th>
<th align="center">PN (8 or 9)</th>
<th align="center">Control (8)</th>
<th align="center"><italic>F</italic> Value</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT, IU/L</td>
<td>36.3 ± 12.7 (25.6–46.9)</td>
<td>84.8 ± 71.8 <sup><xref ref-type="table-fn" rid="table-fn6-0148607111424412">a</xref>,<xref ref-type="table-fn" rid="table-fn5-0148607111424412">‡</xref></sup> (29.6–139.9)</td>
<td>19.6 ± 4.4 (15.9–23.3)</td>
<td>5.107</td>
<td>.015</td>
</tr>
<tr>
<td>AST, IU/L</td>
<td>68.1 ± 18.4<xref ref-type="table-fn" rid="table-fn3-0148607111424412">*</xref> (52.7–83.5)</td>
<td>76.5 ± 12.7 <sup><xref ref-type="table-fn" rid="table-fn7-0148607111424412">b</xref>,</sup><xref ref-type="table-fn" rid="table-fn3-0148607111424412">*</xref> (65.9–87.1)</td>
<td>46.0 ± 8.7 (38.7–53.3)</td>
<td>10.344</td>
<td>.001</td>
</tr>
<tr>
<td>Tbil, µmol/L</td>
<td>6.4 ± 2.8<sup><xref ref-type="table-fn" rid="table-fn4-0148607111424412">†</xref></sup> (4.1–8.7)</td>
<td>10.2 ± 4.6 <sup><xref ref-type="table-fn" rid="table-fn6-0148607111424412">a</xref></sup> (6.7–13.7)</td>
<td>8.8 ± 2.8 (6.5–11.2)</td>
<td>2.530</td>
<td>.103</td>
</tr>
<tr>
<td>Dbil, µmol/L</td>
<td>1.6 ± 0.7 (1.0–2.2)</td>
<td>3.0 ± 1.9 <sup><xref ref-type="table-fn" rid="table-fn7-0148607111424412">b</xref>,<xref ref-type="table-fn" rid="table-fn5-0148607111424412">‡</xref></sup> (1.4–4.6)</td>
<td>0.6 ± 0.4 (0.2–1.0)</td>
<td>8.089</td>
<td>.002</td>
</tr>
<tr>
<td>BA, µmol/L</td>
<td>22.9 ± 6.6<xref ref-type="table-fn" rid="table-fn3-0148607111424412">*</xref> (17.3–28.4)</td>
<td>26.8 ± 3.6 <sup><xref ref-type="table-fn" rid="table-fn7-0148607111424412">b</xref>,</sup><xref ref-type="table-fn" rid="table-fn3-0148607111424412">*</xref> (23.8–29.8)</td>
<td>8.0 ± 2.5 (5.9–10.1)</td>
<td>37.509</td>
<td>.000</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0148607111424412">
<p>ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; BA, bile acid; Dbil, direct bilirubin; mAb, monoclonal antibody treatment; PN, parenteral nutrition; Tbil, total bilirubin.</p>
</fn>
<fn id="table-fn3-0148607111424412">
<label>*</label>
<p><italic>P</italic> &lt; .05, vs control group.</p>
</fn>
<fn id="table-fn4-0148607111424412">
<label>†</label>
<p><italic>P</italic> &lt; .05, vs PN group.</p>
</fn>
<fn id="table-fn5-0148607111424412">
<label>‡</label>
<p><italic>P</italic> &lt; .05, vs PN + mAb and control groups.</p>
</fn>
<fn id="table-fn6-0148607111424412">
<label>a</label>
<p>n = 9 in PN group.</p>
</fn>
<fn id="table-fn7-0148607111424412">
<label>b</label>
<p>n = 8 in PN group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section16-0148607111424412">
<title>Serum TNF-α</title>
<p>Serum TNF-α level in the PN group (n = 6) was significantly higher than the control group (n = 8) and the PN + mAb group (n = 6) (<italic>P</italic> &lt; .05; <xref ref-type="table" rid="table4-0148607111424412">Table 4</xref>).</p>
<table-wrap id="table4-0148607111424412" position="float">
<label>Table 4.</label>
<caption>
<p>Comparison of Serum TNF-α in the 3 Treatment Groups (pg/mL)</p>
</caption>
<graphic alternate-form-of="table4-0148607111424412" xlink:href="10.1177_0148607111424412-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">Group (n)</th>
</tr>
<tr>
<th/>
<th align="center">PN + mAb (6)</th>
<th align="center">PN (6)</th>
<th align="center">Control (8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>28.5 ± 32.4 (1.9–75.5)</td>
<td>83.6 ± 68.7<xref ref-type="table-fn" rid="table-fn9-0148607111424412">*</xref> (6.2–198.5)</td>
<td>28.5 ± 18.1 (1.3–61.3)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0148607111424412">
<p>mAb, monoclonal antibody treatment; PN, parenteral nutrition; TNF-α, tumor necrosis factor–α.</p>
</fn>
<fn id="table-fn9-0148607111424412">
<label>*</label>
<p><italic>P</italic> &lt; .05, vs PN + mAb (<italic>P</italic> = .035) and vs control groups (<italic>P</italic> = .023).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section17-0148607111424412">
<title>Hepatic ABC Transporter Gene Expression</title>
<p>Hepatic mRNA expression levels of <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> mRNA were significantly lower in the PN group relative to the control group (<italic>P</italic> &lt; .05). The PN + mAb group showed higher mRNA expression levels of <italic>mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> relative to the PN group (<italic>P</italic> &lt; .05); the <italic>bsep</italic> mRNA level in this group was twice that measured in the PN group (<xref ref-type="table" rid="table5-0148607111424412">Table 5</xref>).</p>
<table-wrap id="table5-0148607111424412" position="float">
<label>Table 5.</label>
<caption>
<p>Liver <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> mRNA Expression Levels</p>
</caption>
<graphic alternate-form-of="table5-0148607111424412" xlink:href="10.1177_0148607111424412-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">Group (n)</th>
<th/>
<th/>
</tr>
<tr>
<th/>
<th align="center">PN + mAb (10)</th>
<th align="center">PN (13)</th>
<th align="center">Control (10)</th>
<th align="center"><italic>F</italic> Value</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bsep</td>
<td>0.46 ± 0.28 (0.26–0.67)</td>
<td>0.22 ± 0.17<xref ref-type="table-fn" rid="table-fn11-0148607111424412">*</xref> (0.11–0.32)</td>
<td>1.07 ± 0.59 (0.19–0.65)</td>
<td>15.055</td>
<td>.000</td>
</tr>
<tr>
<td>mdr1a/mdr1b</td>
<td>1.36 ± 0.40 (1.07–1.65)</td>
<td>0.42 ± 0.20<sup><xref ref-type="table-fn" rid="table-fn12-0148607111424412">†</xref></sup> (0.30–0.54)</td>
<td>2.01 ± 1.23 (1.13–2.89)</td>
<td>14.120</td>
<td>.000</td>
</tr>
<tr>
<td>mdr2</td>
<td>0.75 ± 0.62 (0.31–1.20)</td>
<td>0.26 ± 0.19<sup><xref ref-type="table-fn" rid="table-fn12-0148607111424412">†</xref></sup> (0.14–0.37)</td>
<td>1.15 ± 0.59 (0.72–1.57)</td>
<td>9.671</td>
<td>.001</td>
</tr>
<tr>
<td>mrp2</td>
<td>1.08 ± 0.71 (0.58–1.58)</td>
<td>0.40 ± 0.20<sup><xref ref-type="table-fn" rid="table-fn12-0148607111424412">†</xref></sup> (0.28–0.52)</td>
<td>1.12 ± 0.46 (0.79–1.46)</td>
<td>8.500</td>
<td>.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0148607111424412">
<p>mAb, monoclonal antibody treatment; PN, parenteral nutrition.</p>
</fn>
<fn id="table-fn11-0148607111424412">
<label>*</label>
<p><italic>P</italic> &lt; .05, vs control group.</p>
</fn>
<fn id="table-fn12-0148607111424412">
<label>†</label>
<p><italic>P</italic> &lt; .05, vs PN + mAb and control groups.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section18-0148607111424412">
<title>Correlation Analysis of Histological Scoring and ABC Transporter Gene Expression</title>
<p>The histological scoring of liver samples was related to hepatic <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> mRNA expression (<italic>r</italic> = −0.557, −0.529, −0.467, and −0.441, respectively; <italic>P</italic> &lt; .05).</p>
</sec>
</sec>
<sec id="section19-0148607111424412" sec-type="discussion">
<title>Discussion</title>
<p>This is the first report demonstrating the protective effects of monoclonal TNF-α antibody (infliximab) treatment of PNALD. Administration of infliximab at a single dose of 5 mg/kg via intravenous infusion reversed serum TNF-α levels in a PNALD mouse model, as Barbuio et al<sup><xref ref-type="bibr" rid="bibr18-0148607111424412">18</xref></sup> reported in rats fed a high-fat diet; reduced PNALD pathologic manifestation; and decreased serum ALT and serum bilirubin levels. An improvement in serum levels of AST and BA was also observed. These findings suggested that TNF-α antibody (infliximab) might be beneficial in the treatment of PNALD.</p>
<p>The mouse model of PNALD used in this study showed typical PN-associated liver damage by LM, as well as an increase in serum transaminase, direct bilirubin, and bile acid levels, consistent with early stage cholestasis. Furthermore, the increase in serum TNF-α seen in the PN group was similar to that previously observed in PN rats.<sup><xref ref-type="bibr" rid="bibr10-0148607111424412">10</xref></sup> Although TNF-α biology in health and disease is complex and continues to be elucidated by ongoing studies, TNF-α is generally thought to function as a proinflammatory cytokine in most diseases. TNF-α has been implicated in some forms of cholestasis, including experimental cholestasis induced by bile duct ligation (BDL),<sup><xref ref-type="bibr" rid="bibr11-0148607111424412">11</xref>,<xref ref-type="bibr" rid="bibr24-0148607111424412">24</xref></sup> sepsis, and viral hepatitis.<sup><xref ref-type="bibr" rid="bibr25-0148607111424412">25</xref></sup> Furthermore, hepatic macrophages from cholestatic liver exhibit high TNF-α levels.<sup><xref ref-type="bibr" rid="bibr26-0148607111424412">26</xref></sup> In a rat model, anti–TNF-α antibody was shown to block endotoxin-associated cholestasis,<sup><xref ref-type="bibr" rid="bibr27-0148607111424412">27</xref></sup> ameliorate PN-related steatosis,<sup><xref ref-type="bibr" rid="bibr20-0148607111424412">20</xref></sup> and improve cholestasis and renal insufficiency in BDL.<sup><xref ref-type="bibr" rid="bibr28-0148607111424412">28</xref></sup></p>
<p>Infliximab is an anti–TNF-α monoclonal antibody with high affinity for the soluble and transmembrane forms of TNF-α. Effective binding of TNF-α with its receptor is inhibited by infliximab and results in neutralization of the biological activity of TNF-α, including its central effect in the proinflammatory cytokine cascade, cytotoxicity, immune regulation, and apoptosis.<sup><xref ref-type="bibr" rid="bibr29-0148607111424412">29</xref></sup> A decade of clinical observation on infliximab treatment had proved that this medicine was safe and efficacious as an anti-inflammatory treatment for Crohn disease, inflammatory bowel disease, and rheumatoid arthritis,<sup><xref ref-type="bibr" rid="bibr30-0148607111424412">30</xref>-<xref ref-type="bibr" rid="bibr34-0148607111424412">34</xref></sup> but the infection complication of infliximab administration had been reported related to its immunosuppressive effects.<sup><xref ref-type="bibr" rid="bibr35-0148607111424412">35</xref>,<xref ref-type="bibr" rid="bibr36-0148607111424412">36</xref></sup> Infection is a well-known factor for PNALD,<sup><xref ref-type="bibr" rid="bibr37-0148607111424412">37</xref>,<xref ref-type="bibr" rid="bibr38-0148607111424412">38</xref></sup> and PN patients are at high risk of infections caused by central catheter–related infection,<sup><xref ref-type="bibr" rid="bibr39-0148607111424412">39</xref>,<xref ref-type="bibr" rid="bibr40-0148607111424412">40</xref></sup> intestinal bacterial translocation, and a systemic or local mucosal barrier deprived from long-term fasting.<sup><xref ref-type="bibr" rid="bibr41-0148607111424412">41</xref>-<xref ref-type="bibr" rid="bibr43-0148607111424412">43</xref></sup> Although infection incidence was not compared among the 3 groups in this study, the serum TNF-α concentration of the infliximab treatment group decreased significantly compared to the PN group and was almost the same as the control group. Thus, the effect of single-dose infliximab seemed to offset the PN-induced elevated serum TNF-α level, with no evidence that infliximab administration impaired this cytokine production in response to the PN experimental procedure. Of course, the underlying mechanism of infliximab-associated infection remains to be elucidated.</p>
<p>Tazuke et al<sup><xref ref-type="bibr" rid="bibr15-0148607111424412">15</xref></sup> reported a decreased level of <italic>mdr2</italic> mRNA in the mouse model of PNAC; however, no histological damage was observed in the liver. The findings showed that a decreased level of <italic>mdr2</italic> mRNA might disrupt a hepatobiliary adaptive mechanism and cause PNAC. Correlation analysis in this study suggested that ABC transporter mRNA expression was related to the degree of liver pathology measured by histological scoring. The PN mice showed decreased levels of <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic> mRNA compared with the control group. However, TNF-α antibody (infliximab) treatment was associated with improved expression of <italic>mdr1, mdr2</italic>, and <italic>mrp2</italic> mRNA, apart from <italic>bsep;</italic> the level of <italic>bsep</italic> mRNA in the PN + mAb group was twice that of the PN group. According to the reported biological function of <italic>bsep, mdr1a</italic>/<italic>mdr1b, mdr2</italic>, and <italic>mrp2</italic>, members of the ABC transporter family, PN with TNF-α antibody (infliximab) administration probably has a tendency to increase secretion of bile acid, xenobiotic compounds, and phosphatidylcholine from hepatic cells into bile.</p>
<p>The results of this study demonstrate that infliximab alleviated PNALD, with upregulation of ABC transporter mRNA expression through an unknown mechanism. Therefore, anti–TNF-α monoclonal antibody may be a beneficial therapy for patients with PNALD.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This work supported by the National Natural Science Foundation of China (grant number 30772270), Shanghai Municipal Health Bureau Research Fund for Natural Science (grant number 2009072), and Program for Innovative Research Team of Shanghai Municipal Education
Commission.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111424412">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dean</surname><given-names>M</given-names></name>
<name><surname>Rzhetsky</surname><given-names>A</given-names></name>
<name><surname>Allikmets</surname><given-names>R</given-names></name>
</person-group>. <article-title>The human ATP-binding cassette (ABC) transporter superfamily</article-title>. <source>Genome Res</source>. <year>2001</year>;<volume>11</volume>:<fpage>1156</fpage>-<lpage>1166</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111424412">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borst</surname><given-names>P</given-names></name>
<name><surname>Elferink</surname><given-names>RO</given-names></name>
</person-group>. <article-title>Mammalian ABC transporters in health and disease</article-title>. <source>Annu Rev Biochem</source>. <year>2002</year>;<volume>71</volume>:<fpage>537</fpage>-<lpage>592</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111424412">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trauner</surname><given-names>M</given-names></name>
</person-group>. <article-title>Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations</article-title>. <source>Yale J Biol Med</source>. <year>1997</year>;<volume>70</volume>:<fpage>365</fpage>-<lpage>378</lpage>.</citation>
</ref> <ref id="bibr4-0148607111424412">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller</surname><given-names>M</given-names></name>
<name><surname>Roelofsen</surname><given-names>H</given-names></name>
<name><surname>Jansen</surname><given-names>PL</given-names></name>
</person-group>. <article-title>Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein</article-title>. <source>Semin Liver Dis</source>. <year>1996</year>;<volume>16</volume>:<fpage>211</fpage>-<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111424412">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oude Elferink</surname><given-names>R</given-names></name>
<name><surname>Meijer</surname><given-names>D</given-names></name>
<name><surname>Kuipers</surname><given-names>F</given-names></name>
<name><surname>Jansen</surname><given-names>PL</given-names></name>
<name><surname>Groen</surname><given-names>AK</given-names></name>
<name><surname>Groothuis</surname><given-names>GM</given-names></name>
</person-group>. <article-title>Hepatobiliary secretion of organic compounds: molecular mechanisms of membrane transport</article-title>. <source>Biochim Biophys Acta</source>. <year>1995</year>;<volume>1241</volume>:<fpage>215</fpage>-<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr6-0148607111424412">
<label>6.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Balistreri</surname><given-names>W</given-names></name>
<name><surname>Bezerra</surname><given-names>J</given-names></name>
<name><surname>Jansen</surname><given-names>P</given-names></name>
<name><surname>Karpen</surname><given-names>SJ</given-names></name>
<name><surname>Shneider</surname><given-names>BL</given-names></name>
<name><surname>Suchy</surname><given-names>FJ</given-names></name>
</person-group>. <article-title>Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference</article-title>. <conf-name>Hepatology</conf-name>. <year>2005</year>;<volume>42</volume>:<fpage>222</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111424412">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trauner</surname><given-names>M</given-names></name>
<name><surname>Wagner</surname><given-names>M</given-names></name>
<name><surname>Fickert</surname><given-names>P</given-names></name>
<name><surname>Zollner</surname><given-names>G</given-names></name>
</person-group>. <article-title>Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis</article-title>. <source>J Clin Gastroenterol</source>. <year>2005</year>;<volume>39</volume>:<fpage>S111</fpage>-<lpage>S124</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111424412">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quigley</surname><given-names>EMM</given-names></name>
<name><surname>Marsh</surname><given-names>MN</given-names></name>
<name><surname>Shaffer</surname><given-names>JL</given-names></name>
<name><surname>Markin</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Hepatobiliary complications of total parenteral nutrition</article-title>. <source>Gastroenterology</source>. <year>1993</year>;<volume>104</volume>:<fpage>286</fpage>-<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111424412">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Btaiche</surname><given-names>IF</given-names></name>
<name><surname>Khalidi</surname><given-names>N</given-names></name>
</person-group>. <article-title>Parenteral nutrition–associated liver complications in children</article-title>. <source>Pharmacotherapy</source>. <year>2002</year>;<volume>22</volume>:<fpage>188</fpage>-<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111424412">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>YJ</given-names></name>
<name><surname>Tam</surname><given-names>YK</given-names></name>
<name><surname>Coutts</surname><given-names>RT</given-names></name>
</person-group>. <article-title>Endotoxin and cytokine released during parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>:<fpage>163</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111424412">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gäbele</surname><given-names>E</given-names></name>
<name><surname>Froh</surname><given-names>M</given-names></name>
<name><surname>Arteel</surname><given-names>GE</given-names></name>
<etal/>
</person-group>. <article-title>TNFα is required for cholestasis-induced liver fibrosis in the mouse</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2009</year>;<volume>378</volume>:<fpage>348</fpage>-<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111424412">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forrest</surname><given-names>EH</given-names></name>
<name><surname>Oien</surname><given-names>KA</given-names></name>
<name><surname>Dickson</surname><given-names>S</given-names></name>
<name><surname>Galloway</surname><given-names>D</given-names></name>
<name><surname>Mills</surname><given-names>PR</given-names></name>
</person-group>. <article-title>Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha</article-title>. <source>Liver</source>. <year>2002</year>;<volume>22</volume>:<fpage>317</fpage>-<lpage>320</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111424412">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Knight</surname><given-names>DM</given-names></name>
<name><surname>Trinh</surname><given-names>H</given-names></name>
<name><surname>Le</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Construction and initial characterization of a mouse human chimeric anti-TNF antibody</article-title>. <source>Mol Immunol</source>. <year>1993</year>;<volume>30</volume>:<fpage>1443</fpage>-<lpage>1453</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111424412">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scallon</surname><given-names>BJ</given-names></name>
<name><surname>Moore</surname><given-names>MA</given-names></name>
<name><surname>Trinh</surname><given-names>H</given-names></name>
<name><surname>Knight</surname><given-names>DM</given-names></name>
<name><surname>Ghrayeb</surname><given-names>J</given-names></name>
</person-group>. <article-title>Chimeric anti-TNFα monoclonal antibody Ca2binds recombinant transmembrane TNFα and activates immune effector functions</article-title>. <source>Cytokine</source>. <year>1995</year>;<volume>7</volume>:<fpage>251</fpage>-<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111424412">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tazuke</surname><given-names>Y</given-names></name>
<name><surname>Kiristioglu</surname><given-names>I</given-names></name>
<name><surname>Heidelberger</surname><given-names>KP</given-names></name>
<name><surname>Eisenbraun</surname><given-names>MD</given-names></name>
<name><surname>Teitelbaum</surname><given-names>DH</given-names></name>
</person-group>. <article-title>Hepatic P-glycoprotein changes with total parenteral nutrition administration</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>:<fpage>1</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111424412">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tracey</surname><given-names>D</given-names></name>
<name><surname>Klareskog</surname><given-names>L</given-names></name>
<name><surname>Sasso</surname><given-names>EH</given-names></name>
<name><surname>Salfeld</surname><given-names>JG</given-names></name>
<name><surname>Tak</surname><given-names>PP</given-names></name>
</person-group>. <article-title>Tumor necrosis factor antagonist mechanisms of action: a comprehensive review</article-title>. <source>Pharmacol Ther</source>. <year>2008</year>;<volume>117</volume>:<fpage>244</fpage>-<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111424412">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koca</surname><given-names>SS</given-names></name>
<name><surname>Bahcecioglu</surname><given-names>IH</given-names></name>
<name><surname>Poyrazoglu</surname><given-names>OK</given-names></name>
<name><surname>Ozercan</surname><given-names>IH</given-names></name>
<name><surname>Sahin</surname><given-names>K</given-names></name>
<name><surname>Ustundag</surname><given-names>B</given-names></name>
</person-group>. <article-title>The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet</article-title>. <source>Inflammation</source>. <year>2008</year>;<volume>31</volume>:<fpage>91</fpage>-<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111424412">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbuio</surname><given-names>R</given-names></name>
<name><surname>Milanski</surname><given-names>M</given-names></name>
<name><surname>Bertolo</surname><given-names>MB</given-names></name>
<name><surname>Saad</surname><given-names>MJ</given-names></name>
<name><surname>Velloso</surname><given-names>LA</given-names></name>
</person-group>. <article-title>Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet</article-title>. <source>J Endocrinol</source>. <year>2007</year>;<volume>194</volume>:<fpage>539</fpage>-<lpage>550</lpage>.</citation>
</ref>
<ref id="bibr19-0148607111424412">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bahcecioglu</surname><given-names>IH</given-names></name>
<name><surname>Koca</surname><given-names>SS</given-names></name>
<name><surname>Poyrazoglu</surname><given-names>OK</given-names></name>
<etal/>
</person-group>. <article-title>Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis</article-title>. <source>Inflammation</source>. <year>2008</year>;<volume>31</volume>:<fpage>215</fpage>-<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111424412">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pappo</surname><given-names>I</given-names></name>
<name><surname>Bercovier</surname><given-names>H</given-names></name>
<name><surname>Berry</surname><given-names>E</given-names></name>
<name><surname>Gallilly</surname><given-names>R</given-names></name>
<name><surname>Feigin</surname><given-names>E</given-names></name>
<name><surname>Freund</surname><given-names>HR</given-names></name>
</person-group>. <article-title>Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1995</year>;<volume>19</volume>:<fpage>80</fpage>-<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111424412">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loff</surname><given-names>S</given-names></name>
<name><surname>Waag</surname><given-names>KL</given-names></name>
<name><surname>Kranzlin</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Long-term total parenteral nutrition induced hepatobiliary dysfunction in a rabbit model</article-title>. <source>J Pediatr Surg</source>. <year>1998</year>;<volume>33</volume>:<fpage>694</fpage>-<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr22-0148607111424412">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Cai</surname><given-names>W</given-names></name>
<name><surname>Hong</surname><given-names>L</given-names></name>
<name><surname>Tang</surname><given-names>Q</given-names></name>
</person-group>. <article-title><italic>Bifidobacterium adolescentis</italic> supplementation ameliorates parenteral nutrition–induced liver injury in infant rabbits</article-title>. <source>Dig Dis Sci</source>. <year>2010</year>;<volume>55</volume>:<fpage>2814</fpage>-<lpage>2820</lpage>.</citation>
</ref>
<ref id="bibr23-0148607111424412">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Larionov</surname><given-names>A</given-names></name>
<name><surname>Krause</surname><given-names>A</given-names></name>
<name><surname>Miller</surname><given-names>W</given-names></name>
</person-group>. <article-title>A standard curve based method for relative real time PCR data processing</article-title>. <source>BMC Bioinformatics</source>. <year>2005</year>;<volume>6</volume>:<fpage>62</fpage>-<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr24-0148607111424412">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bemelmans</surname><given-names>MH</given-names></name>
<name><surname>Gouma</surname><given-names>DJ</given-names></name>
<name><surname>Greve</surname><given-names>JW</given-names></name>
<name><surname>Buurman</surname><given-names>WA</given-names></name>
</person-group>. <article-title>Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice</article-title>. <source>Hepatology</source>. <year>1992</year>;<volume>15</volume>:<fpage>1132</fpage>-<lpage>1136</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111424412">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshioka</surname><given-names>K</given-names></name>
<name><surname>Kakumu</surname><given-names>S</given-names></name>
<name><surname>Arao</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Immunohistochemical studies of intrahepatic tumor necrosis factor in chronic liver disease</article-title>. <source>J Clin Pathol</source>. <year>1990</year>;<volume>43</volume>:<fpage>298</fpage>-<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr26-0148607111424412">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fox</surname><given-names>ES</given-names></name>
<name><surname>Kim</surname><given-names>JC</given-names></name>
<name><surname>Tracy</surname><given-names>TF</given-names></name>
</person-group>. <article-title>NF-kappa B activation and modulation in hepatic macrophages during cholestatic injury</article-title>. <source>J Surg Res</source>. <year>1997</year>;<volume>72</volume>:<fpage>129</fpage>-<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr27-0148607111424412">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whiting</surname><given-names>JF</given-names></name>
<name><surname>Green</surname><given-names>RM</given-names></name>
<name><surname>Rosenbluth</surname><given-names>AB</given-names></name>
<name><surname>Gollan</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Tumor necrosis factor–alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis</article-title>. <source>Hepatology</source>. <year>1995</year>;<volume>22</volume>:<fpage>1273</fpage>-<lpage>1278</lpage>.</citation>
</ref>
<ref id="bibr28-0148607111424412">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Padillo</surname><given-names>FJ</given-names></name>
<name><surname>Cruz</surname><given-names>A</given-names></name>
<name><surname>Segura-Jiménez</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Anti-TNF-alpha treatment and bile duct drainage restore cellular immunity and prevent tissue injury in experimental obstructive jaundice</article-title>. <source>Int J Immunopathol Pharmacol</source>. <year>2007</year>;<volume>20</volume>:<fpage>855</fpage>-<lpage>860</lpage>.</citation>
</ref>
<ref id="bibr29-0148607111424412">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feldmann</surname><given-names>M</given-names></name>
</person-group>. <article-title>Development of anti-TNF therapy for rheumatoid arthritis</article-title>. <source>Nat Rev Immunol</source>. <year>2002</year>;<volume>2</volume>:<fpage>364</fpage>-<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr30-0148607111424412">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borrelli</surname><given-names>O</given-names></name>
<name><surname>Bascietto</surname><given-names>C</given-names></name>
<name><surname>Viola</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease</article-title>. <source>Dig Liver Dis</source>. <year>2004</year>;<volume>36</volume>:<fpage>342</fpage>-<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr31-0148607111424412">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sands</surname><given-names>B</given-names></name>
<name><surname>Blank</surname><given-names>M</given-names></name>
<name><surname>Diamond</surname><given-names>R</given-names></name>
<name><surname>Barrett</surname><given-names>J</given-names></name>
<name><surname>van Deventer</surname><given-names>S</given-names></name>
</person-group>. <article-title>Maintenance infliximab does not result in increased abscess development in fitulizing Crohn’s disease: results from the ACCENT II study</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2006</year>;<volume>23</volume>:<fpage>1127</fpage>-<lpage>1136</lpage>.</citation>
</ref>
<ref id="bibr32-0148607111424412">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Donnell</surname><given-names>S</given-names></name>
<name><surname>Murphy</surname><given-names>S</given-names></name>
<name><surname>Anwar</surname><given-names>MM</given-names></name>
<etal/>
</person-group>. <article-title>Safety of infliximab in 10 years of clinical practice</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2011</year>;<volume>23</volume>:<fpage>603</fpage>-<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr33-0148607111424412">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orlando</surname><given-names>A</given-names></name>
<name><surname>Mocciaro</surname><given-names>F</given-names></name>
<name><surname>Civitavecchia</surname><given-names>G</given-names></name>
<name><surname>Scimeca</surname><given-names>D</given-names></name>
<name><surname>Cottone</surname><given-names>M</given-names></name>
</person-group>. <article-title>Minimizing infliximab toxicity in the treatment of inflammatory bowel disease</article-title>. <source>Dig Liver Dis</source>. <year>2008</year>;<volume>40</volume>:<fpage>S236</fpage>-<lpage>S246</lpage>.</citation>
</ref>
<ref id="bibr34-0148607111424412">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flendrie</surname><given-names>M</given-names></name>
<name><surname>Creemers</surname><given-names>MC</given-names></name>
<name><surname>Welsing</surname><given-names>PM</given-names></name>
<name><surname>van Riel</surname><given-names>PL</given-names></name>
</person-group>. <article-title>The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis: a longitudinal observational study</article-title>. <source>Rheumatol (Oxf)</source>. <year>2005</year>;<volume>44</volume>:<fpage>472</fpage>-<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr35-0148607111424412">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Imaizumi</surname><given-names>K</given-names></name>
<name><surname>Sugishita</surname><given-names>M</given-names></name>
<name><surname>Usui</surname><given-names>M</given-names></name>
<name><surname>Kawabe</surname><given-names>T</given-names></name>
<name><surname>Hashimoto</surname><given-names>N</given-names></name>
<name><surname>Hasegawa</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Pulmonary infectious complications associated with anti–TNF alpha therapy (infliximab) for rheumatoid arthritis</article-title>. <source>Intern Med</source>. <year>2006</year>;<volume>45</volume>:<fpage>685</fpage>-<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr36-0148607111424412">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneeweiss</surname><given-names>S</given-names></name>
<name><surname>Korzenik</surname><given-names>J</given-names></name>
<name><surname>Solomon</surname><given-names>DH</given-names></name>
<name><surname>Canning</surname><given-names>C</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Bressler</surname><given-names>B</given-names></name>
</person-group>. <article-title>Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2009</year>;<volume>30</volume>:<fpage>253</fpage>-<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr37-0148607111424412">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colomb</surname><given-names>V</given-names></name>
<name><surname>Goulet</surname><given-names>O</given-names></name>
<name><surname>Rambaud</surname><given-names>C</given-names></name>
<name><surname>De Potter</surname><given-names>S</given-names></name>
<name><surname>Sadoun</surname><given-names>E</given-names></name>
<name><surname>BenHariz</surname><given-names>M</given-names></name>
</person-group>. <article-title>Long term parenteral nutrition (PN) in children: liver and gallbladder disease</article-title>. <source>Transplant Proc</source>. <year>1992</year>;<volume>24</volume>:<fpage>1045</fpage>-<lpage>1055</lpage>.</citation>
</ref>
<ref id="bibr38-0148607111424412">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moseley</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Sepsis-associated cholestasis</article-title>. <source>Gastroenterology</source>. <year>1997</year>;<volume>112</volume>:<fpage>302</fpage>-<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr39-0148607111424412">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reimund</surname><given-names>JM</given-names></name>
<name><surname>Arondel</surname><given-names>Y</given-names></name>
<name><surname>Finck</surname><given-names>G</given-names></name>
<name><surname>Zimmermann</surname><given-names>F</given-names></name>
<name><surname>Duclos</surname><given-names>B</given-names></name>
<name><surname>Baumann</surname><given-names>R</given-names></name>
</person-group>. <article-title>Catheter-related infection in patients on home parenteral nutrition: results of a prospective survey</article-title>. <source>Clin Nutr</source>. <year>2002</year>;<volume>21</volume>:<fpage>33</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr40-0148607111424412">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santarpia</surname><given-names>L</given-names></name>
<name><surname>Alfonsi</surname><given-names>L</given-names></name>
<name><surname>Tiseo</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Central venous catheter infections and antibiotic therapy during long-term home parenteral nutrition: an 11-year follow-up study</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>:<fpage>254</fpage>-<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr41-0148607111424412">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shou</surname><given-names>J</given-names></name>
<name><surname>Lappin</surname><given-names>J</given-names></name>
<name><surname>Minnard</surname><given-names>EA</given-names></name>
<name><surname>Daly</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Total parenteral nutrition, bacterial translocation, and host immune function</article-title>. <source>Am J Surg</source>. <year>1994</year>;<volume>167</volume>:<fpage>145</fpage>-<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr42-0148607111424412">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okada</surname><given-names>Y</given-names></name>
<name><surname>Klein</surname><given-names>NJ</given-names></name>
<name><surname>van Saene</surname><given-names>HK</given-names></name>
<name><surname>Webb</surname><given-names>G</given-names></name>
<name><surname>Holzel</surname><given-names>H</given-names></name>
<name><surname>Pierro</surname><given-names>A</given-names></name>
</person-group>. <article-title>Bactericidal activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition</article-title>. <source>Ann Surg</source>. <year>2000</year>;<volume>231</volume>:<fpage>276</fpage>-<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr43-0148607111424412">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>D</given-names></name>
<name><surname>Lu</surname><given-names>Q</given-names></name>
<name><surname>Deitch</surname><given-names>EA</given-names></name>
</person-group>. <article-title>Elemental diet-induced bacterial translocation associated with systemic and intestinal immune suppression</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1998</year>;<volume>22</volume>:<fpage>37</fpage>-<lpage>41</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>